The Effect of Zongertinib on the Pharmacokinetics of Dabigatran (Part 1) and Rosuvastatin, Metformin and Furosemide Administered as a Cocktail (Part 2) in Healthy Male Subjects (a 2- Part, Open-label, 2-period, Fixed-sequence Cross-over Trial)

For Part 1 of the trial, the main objective is to assess the effect of a single dose of zongertinib on the pharmacokinetics of a single dose of dabigatran-etexilate. For Part 2 of the trial, the main objective is to assess the effect of zongertinib at steady-state on the pharmacokinetics of a single dose of rosuvastatin, metformin and furosemide (administered as a cocktail).

开始日期2024-08-19

申办/合作机构

Boehringer Ingelheim GmbH

NCT06494761 / Not yet recruiting临床1期

The Effect of Multiple Doses of Zongertinib on the Single-dose Pharmacokinetics of Midazolam, Omeprazole and Repaglinide in Healthy Male Subjects (an Open-label, 2-period, Fixed-sequence Trial)

The main objective of this trial is to assess the effect of multiple oral doses of zongertinib on the pharmacokinetics of midazolam, omeprazole and repaglinide.

开始日期2024-07-22

申办/合作机构

Boehringer Ingelheim GmbH

NCT06324357 / Recruiting临床1/2期

Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination With Intravenous Trastuzumab Deruxtecan (T-DXd) or in Combination With Intravenous Trastuzumab Emtansine (T-DM1) for Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC) and Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC)

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (T-DXd) or with trastuzumab emtansine (T-DM1). Another purpose is to check whether zongertinib in combination with T-DXd or with T-DM1 can make tumours shrink. Zongertinib inhibits HER2. HER2 causes cancer cells to grow.
The study is split into treatment cycles. All study participants are treated with zongertinib in combination with T-DXd or with T-DM1. This study has 2 parts. In Part 1, participants receive increasing doses of zongertinib. In Part 2, participants are put into different groups by chance. Each group receives a different dose of zongertinib. Every participant has an equal chance of being in each group.
During the study, the participants visit the study site regularly. In this study, researchers want to find the highest dose of zongertinib that participants can tolerate when taken together with T-DXd or with T-DM1. To find this out, researchers look at certain severe health problems that a number of participants have. The doctors regularly check the size of the tumour with imaging methods (CT/MRI) during the study. The doctors also regularly check participants' health and take note of any unwanted effects.

开始日期2024-05-23

申办/合作机构

Boehringer Ingelheim GmbH

100 项与 Zongertinib 相关的临床结果

登录后查看更多信息

100 项与 Zongertinib 相关的转化医学

登录后查看更多信息

100 项与 Zongertinib 相关的专利（医药）

登录后查看更多信息

项与 Zongertinib 相关的文献（医药）

2023-03-01·Clinical lung cancer

A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations

Article

作者: Sadrolhefazi, Behbood ; Gibson, Neil ; Barve, Minal ; Opdam, Frans ; Yamamoto, Noboru ; Heymach, John ; Serra, Josep

BACKGROUND:

BI 1810631 is a human HER2-selective tyrosine kinase inhibitor that covalently binds to both wild-type and mutated HER2 receptors, including exon 20 insertion mutations, whilst sparing EGFR signaling. This phase Ia/Ib, open-label, non-randomized study will determine the safety, maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BI 1810631 in patients with HER2 aberration-positive solid tumors (NCT04886804).

PATIENTS AND METHODS:

In phase Ia, patients with histologically/cytologically confirmed HER2 aberration-positive advanced/metastatic solid tumors will receive BI 1810631 orally twice daily (BID) or once daily (QD) at escalating doses. Starting dose level is 15 mg BID; QD schedule will begin after one dose level above estimated therapeutic dose of BI 1810631 is determined safe by the Dose Escalation Committee. Dose escalation will continue until MTD/recommended phase II dose and preferred phase Ib schedule for each schedule is determined. In phase Ib, patients with HER2 tyrosine kinase domain (TKD) mutation-positive non-small cell lung cancer (NSCLC) who have previously received ≥1 line of systemic therapy will be enrolled initially, with possible inclusion of additional NSCLC cohorts in the future, including untreated patients. The primary endpoints will be MTD based on number of dose-limiting toxicities (DLTs)/number of patients with DLTs (phase Ia) and objective response (phase Ib). Secondary endpoints include PK parameters (phase Ia/Ib); duration of response, disease control, duration of disease control, and progression-free survival (phase Ib).

CONCLUSIONS:

BI 1810631 could be an effective and tolerable EGFR-sparing oral treatment for patients with HER2 mutation-positive NSCLC, including exon 20 insertion mutations.

CLINICALTRIALS:

GOV IDENTIFIER:

NCT04886804.

项与 Zongertinib 相关的新闻（医药）

2024-07-19

·echemi

Boehringer Ingelheim Reports 7.4% Sales Growth to €12.9 Billion in the First Half of 2024

Boehringer Ingelheim delivered a solid business performance in the first half of 2024, achieving a significant increase in net sales, up 7.4% year-on-year to €12.9 billion. This strong growth was mainly driven by the outstanding performance of its pharmaceutical business, in particular the market leadership of the Ou Tangjing ® and Vegat ® family products, which further consolidated the company's leading position in the global pharmaceutical industry. In response to growing market demand, Boehringer Ingelheim has increased its investment in the production and supply network. Earlier this year, the company announced that it will invest €120 million to upgrade and expand its pharmaceutical facility in Koropi, Greece, to increase the capacity of new and existing products, including some innovative products in advanced development, to meet the high quality medicines that patients around the world have come to expect. In key therapeutic areas, Boehringer Ingelheim has made significant progress. In the coming year, the company plans to release more positive results from clinical studies in areas such as oncology, mental health and pulmonary fibrosis. For example, Zongertinib in oncology, Iclepertin in mental health, and Nerandomilast in pulmonary fibrosis all show great potential to bring new treatment options to patients. In the field of cardiorenal metabolic health, Boehringer Ingelheim's research has also achieved a milestone breakthrough. survodutide has shown encouraging results in a Phase II clinical trial for the treatment of steatohepatitis (MASH) associated with metabolic dysfunction, with 83% of patients achieving significant improvement after receiving the treatment. In addition, a subgroup analysis further confirmed that 64.5% of patients with moderate to advanced fibrosis improved their fibrosis degree and did not worsen their disease after treatment. Boehringer Ingelheim has also initiated a number of Phase III clinical trials, including a novel selective aldosterone synthetase inhibitor (ASi) in combination with Englipzin for chronic heart failure, and a trial of ASi for chronic kidney disease in collaboration with Oxford Population Health to explore broader therapeutic possibilities. In addition, Boehringer Ingelheim has a multi-year sponsorship agreement with the American Heart Association's Cardio-Renal Metabolic Health Initiative, which aims to gain a deeper understanding of the impact of cardio-renal metabolic related diseases on patients, leading to the development of more effective treatment strategies. Boehringer Ingelheim's determination to return to the field of oncology therapy is also reflected in the fact that its HER2-specific tyrosine kinase inhibitor Zongertinib is currently in clinical study for HER2-variant cancers, promising to revolutionize treatment options in this field. Boehringer Ingelheim's strong results and continued investment in innovation in the first half of 2024 demonstrate the company's solid development in the global pharmaceutical market and its strong commitment to the needs of patients.

AHA会议临床2期临床结果临床3期

2024-07-18

·美通社

勃林格殷格翰2024年上半年成绩单出炉：加速推进产品管线，达成重要里程碑

公司在心肾代谢健康与肿瘤领域达成多项里程碑年内肿瘤、精神健康与肺纤维化领域的临床研究将发布最新数据上半年净销售额同比实现7.4%*的强劲增长上海 2024年7月18日 /美通社/ -- 7月18日，以研发驱动的全球生物制药领军企业勃林格殷格翰发布了2024年上半年业绩。今年上半年，公司大幅加速推进关键治疗领域的产品管线，达成多项重要里程碑。勃林格殷格翰全球执行董事会主席冯保和（Hubertus von Baumbach）先生表示："我们在4月公布的公司研发规划的基础上，进一步加大研发投入。针对代谢功能障碍相关的脂肪性肝炎，我们已公布了振奋人心的研究数据。接下来，我们还将发布肿瘤、精神健康与肺纤维化领域的最新研究结果。这些新进展给予了我们充足信心，加速推动这些晚期在研药物上市前准备。我们非常高兴看到公司产品管线飞速发展。" 勃林格殷格翰持续推进处在不同临床试验阶段的研发管线。上半年，公司在心血管代谢疾病、精神健康与肿瘤领域启动了5项新的I期、II期或III期临床试验；在炎症性疾病领域，公司的在研产品也成功获得2项快速通道资格认定。与此同时，公司宣布达成9项研发合作协议，覆盖各治疗领域与技术平台，极大增强了公司的人用药品产品组合。勃林格殷格翰全球执行董事会成员、财务负责人Frank Hübler表示："随着我们研发管线在深度与广度持续拓展，我们在资源配置时保持高度专注。我们希望竭尽所能加速产品研发，将我们的创新药品更快惠及患者。" 在持续强劲的市场需求拉动下，2024年上半年公司净销售额同比增长7.4%*至129亿欧元，包括人用药品业务的欧唐静 ® 家族与维加特 ® ，以及动物保健业务的尼可信 ® 家族产品等在内的多个勃林格产品驱动增长。人用药品业务勃林格殷格翰积极为未来产品组合以及即将上市的产品做准备。过去几个月，公司在所有重点治疗领域都取得进展。年内，公司还将发布肿瘤（Zongertinib）、精神健康（Iclepertin）与肺纤维化（Nerandomilast）领域临床研究的更多最新结果。公司在促进整体心肾脏代谢 (CRM) 健康方面的研究努力达成一系列重要里程碑。其中，survodutide治疗代谢功能障碍相关的脂肪性肝炎（MASH）的II期临床试验取得突破性的积极结果：与安慰剂(18.2%)相比，高达83%接受survodutide治疗的MASH成人患者实现了具有统计学意义的改善[组间差异：64.8%，(CI 51.1% - 78.6%), p<0.0001]。此外，该试验一项亚组分析结果显示，与安慰剂(25.9%)相比，多达64.5%的F2和F3期纤维化（中度至晚期疤痕）成人患者的纤维化程度得到改善，且MASH无恶化 [组间差异：38.6%，(95% CI 18.1% - 59.1%), p=0.0005]。 [1] 公司启动了一项新型选择性醛固酮合酶抑制剂（ASi）联合恩格列净治疗慢性心力衰竭患者的III期临床试验。勃林格殷格翰还将与牛津人口健康中心合作，开展一项使用Asi治疗慢性肾病的III期临床试验。此外，勃林格殷格翰已与美国心脏协会心肾代谢健康倡议达成多年赞助协议。这一最新宣布的举措将帮助公司更好地了解心肾代谢关联性疾病患者的负担，从而提供更好的治疗方案。勃林格殷格翰致力于通过定向投资重返肿瘤治疗领域。HER2特异性酪氨酸激酶抑制剂Zongertinib治疗HER2 变异阳性实体瘤患者的Ia/Ib期试验结果表明，Zongertinib展现出良好的耐受性与显著的有效性 [2] 。此外，尽管Brigimadlin治疗去分化脂肪肉瘤的Brightline-1临床试验未达到主要终点，但获益-风险评估结果仍为阳性。完整的试验结果将于年内晚些的医学会议上公布。这两项临床试验结果将于近几个月的医学会议上公布。 2024年上半年，勃林格殷格翰人用药品业务净销售额同比增长9.3%*达103亿欧元，主要得益于欧唐静 ® 家族和维加特 ® 的强劲表现。为了满足不断增长的市场需求，勃林格殷格翰对生产与供应网络持续高位投资。今年1月，勃林格殷格翰宣布投资1.2亿欧元升级扩建位于希腊Koropi的工厂，旨在提升新上市与现有药品的产能，包括处于晚期开发阶段的一些在研产品。动物保健业务在畜禽业务领域，家禽疫苗VAXXITEK产品组合持续拓展，增长16%。公司新推出了一款保护牛羊免受血清3型蓝舌病病毒（BTV-3）感染的新疫苗：BULTAVO 3™。这是首个能够预防临床症状与死亡的BTV-3疫苗。目前BULTAVO 3™ 已在荷兰、比利时和德国获得紧急使用许可。近期这三个国家爆发的BTV-3疫情给当地农场主造成严重损失，并对邻国构成威胁。今年上半年，动物保健业务增长低于预期，净销售额同比增长0.9%*至25亿欧元。随着犬用NEXGARD PLUS和猫用NEXGARD COMBO的最新上市，尼可信 ® 系列抗寄生虫产品的净销售额同比增长16%。作为首个获批的犬用抗蜱虫与跳蚤非处方咀嚼片，FRONTPRO ® 现已在欧洲大多数国家上市，并持续推动该区域业绩增长。在宠物治疗产品领域，犬用充血性心衰治疗药物勃欣定的净销售额同比增长16%。管线展望展望未来，人用药品业务预计到2030年将收获多达25项获批上市成果。动物保健业务预计到2026年也将于各地市场收获20项新注册上市成果，包括产品迭代、适应症拓展和新产品上市。 * 经汇率调整后参考文献： 1 Sanyal, Arun J. "Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial". Oral presentation at European Association for the Study of the Liver Congress, Milan, Italy. 7June 2024. Abstract #LB117, presentation #GS-006. 2 Heymach, John. "Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor in patients with HER2 aberration-positive solid tumors: updated Phase Ia data from Beamion LUNG-1, including progression-free survival data”. Oral presentation at American Society of Clinical Oncology, United States, Chicago. 1 June 2024. Abstract #8514 Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at www.boehringer-ingelheim.com. 关于勃林格殷格翰勃林格殷格翰是全球领先的生物制药企业，布局人用药品、动物保健两大业务领域。公司研发投入位居行业前列，致力于研究突破性疗法，解决巨大未满足的医疗需求，从而帮助改善或延长生命。自1885年成立以来，勃林格殷格翰一直是独立的家族企业，始终着眼长远发展，将可持续发展理念贯穿全价值链。公司在全球有超过5.35万名员工，服务逾130个市场，致力于打造一个更健康、更可持续、更公平的未来。更多详情，请访问： www.boehringer-ingelheim.com

临床2期临床3期申请上市临床1期

2024-07-18

·勃林格殷格翰中国

勃林格2024年上半年成绩单出炉：加速推进产品管线，达成重要里程碑

公司在心肾代谢健康与肿瘤领域达成多项里程碑年内肿瘤、精神健康与肺纤维化领域的临床研究将发布最新数据上半年净销售额同比实现7.4%*的强劲增长今天，以研发驱动的全球生物制药领军企业勃林格殷格翰发布了2024年上半年业绩。今年上半年，公司大幅加速推进关键治疗领域的产品管线，达成多项重要里程碑。冯保和(Hubertus von Baumbach) 勃林格殷格翰全球执行董事会主席我们在4月公布的公司研发规划的基础上，进一步加大研发投入。针对代谢功能障碍相关的脂肪性肝炎，我们已公布了振奋人心的研究数据。接下来，我们还将发布肿瘤、精神健康与肺纤维化领域的最新研究结果。这些新进展给予了我们充足信心，加速推动这些晚期在研药物上市前准备。我们非常高兴看到公司产品管线飞速发展。勃林格殷格翰持续推进处在不同临床试验阶段的研发管线。上半年，公司在心血管代谢疾病、精神健康与肿瘤领域启动了5项新的I期、II期或III期临床试验；在炎症性疾病领域，公司的在研产品也成功获得2项快速通道资格认定。与此同时，公司宣布达成9项研发合作协议，覆盖各治疗领域与技术平台，极大增强了公司的人用药品产品组合。 Frank Hübler 勃林格殷格翰全球执行董事会成员财务负责人随着我们研发管线在深度与广度持续拓展，我们在资源配置时保持高度专注。我们希望竭尽所能加速产品研发，将我们的创新药品更快惠及患者。在持续强劲的市场需求拉动下，2024年上半年公司净销售额同比增长7.4%*至129亿欧元，包括人用药品业务的欧唐静®家族与维加特®，以及动物保健业务的尼可信®家族产品等在内的多个勃林格产品驱动增长。人用药品业务勃林格殷格翰积极为未来产品组合以及即将上市的产品做准备。过去几个月，公司在所有重点治疗领域都取得进展。年内，公司还将发布肿瘤(Zongertinib)、精神健康(Iclepertin)与肺纤维化(Nerandomilast)领域临床研究的更多最新结果。公司在促进整体心肾脏代谢(CRM)健康方面的研究努力达成一系列重要里程碑。其中，survodutide治疗代谢功能障碍相关的脂肪性肝炎(MASH)的II期临床试验取得突破性的积极结果：与安慰剂(18.2%)相比，高达83%接受survodutide治疗的MASH成人患者实现了具有统计学意义的改善[组间差异：64.8%，(CI 51.1% - 78.6%), p<0.0001]。此外，该试验一项亚组分析结果显示，与安慰剂(25.9%)相比，多达64.5%的F2和F3期纤维化（中度至晚期疤痕）成人患者的纤维化程度得到改善，且MASH无恶化 [组间差异：38.6%，(95% CI 18.1% - 59.1%), p=0.0005]。1 公司启动了一项新型选择性醛固酮合酶抑制剂(ASi)联合恩格列净治疗慢性心力衰竭患者的III期临床试验。勃林格殷格翰还将与牛津人口健康中心合作，开展一项使用Asi治疗慢性肾病的III期临床试验。此外，勃林格殷格翰已与美国心脏协会心肾代谢健康倡议达成多年赞助协议。这一最新宣布的举措将帮助公司更好地了解心肾代谢关联性疾病患者的负担，从而提供更好的治疗方案。勃林格殷格翰致力于通过定向投资重返肿瘤治疗领域。HER2特异性酪氨酸激酶抑制剂Zongertinib治疗HER2变异阳性实体瘤患者的Ia/Ib期试验结果表明，Zongertinib展现出良好的耐受性与显著的有效性。2 此外，尽管Brigimadlin治疗去分化脂肪肉瘤的Brightline-1临床试验未达到主要终点，但获益-风险评估结果仍为阳性。这两项临床试验结果将于近几个月的医学会议上公布。 2024年上半年，勃林格殷格翰人用药品业务净销售额同比增长9.3%*达103亿欧元，主要得益于欧唐静®家族和维加特®的强劲表现。为了满足不断增长的市场需求，勃林格殷格翰对生产与供应网络持续高位投资。今年1月，勃林格殷格翰宣布投资1.2亿欧元升级扩建位于希腊Koropi的工厂，旨在提升新上市与现有药品的产能，包括处于晚期开发阶段的一些在研产品。动物保健业务在畜禽业务领域，家禽疫苗VAXXITEK产品组合持续拓展，增长16%。公司新推出了一款保护牛羊免受血清3型蓝舌病病毒(BTV-3)感染的新疫苗：BULTAVO 3™。这是首个能够预防临床症状与死亡的BTV-3疫苗。目前BULTAVO 3™ 已在荷兰、比利时和德国获得紧急使用许可。近期这三个国家爆发的BTV-3疫情给当地农场主造成严重损失，并对邻国构成威胁。今年上半年，动物保健业务增长低于预期，净销售额同比增长0.9%*至25亿欧元。随着犬用NEXGARD PLUS和猫用NEXGARD COMBO的最新上市，尼可信®系列抗寄生虫产品的净销售额同比增长16%。作为首个获批的犬用抗蜱虫与跳蚤非处方咀嚼片，FRONTPRO®现已在欧洲大多数国家上市，并持续推动该区域业绩增长。在宠物治疗产品领域，犬用充血性心衰治疗药物勃欣定的净销售额同比增长16%。管线展望展望未来，人用药品业务预计到2030年将收获多达25项获批上市成果。动物保健业务预计到2026年也将于各地市场收获20项新注册上市成果，包括产品迭代、适应症拓展和新产品上市。 *经汇率调整后参考文献 1. Sanyal, Arun J. "Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial”. Oral presentation at European Association for the Study of the Liver Congress, Milan, Italy. 7June 2024. Abstract #LB117, presentation #GS-006. 2. Heymach, John. "Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor in patients with HER2 aberration-positive solid tumors: updated Phase Ia data from Beamion LUNG-1, including progression-free survival data”. Oral presentation at American Society of Clinical Oncology, United States, Chicago. 1 June 2024. Abstract #8514 关于勃林格殷格翰勃林格殷格翰是全球领先的生物制药企业，布局人用药品、动物保健两大业务领域。公司研发投入位居行业前列，致力于研究突破性疗法，解决巨大未满足的医疗需求，从而帮助改善或延长生命。自1885年成立以来，勃林格殷格翰一直是独立的家族企业，始终着眼长远发展，将可持续发展理念贯穿全价值链。公司在全球有超过5.35万名员工，服务逾130个市场，致力于打造一个更健康、更可持续、更公平的未来。更多详情，请访问：www.boehringer-ingelheim.com

临床2期临床3期上市批准申请上市

100 项与 Zongertinib 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HER2突变型非小细胞肺癌	临床3期	美国	Boehringer Ingelheim Pharma GmbH & Co., KG	2024-02-09
HER2突变型非小细胞肺癌	临床3期	美国	Boehringer Ingelheim International GmbH	2024-02-09
HER2突变型非小细胞肺癌	临床3期	日本	Boehringer Ingelheim Pharma GmbH & Co., KG	2024-02-09
HER2突变型非小细胞肺癌	临床3期	日本	Boehringer Ingelheim International GmbH	2024-02-09
HER2突变型非小细胞肺癌	临床3期	澳大利亚	Boehringer Ingelheim Pharma GmbH & Co., KG	2024-02-09
HER2突变型非小细胞肺癌	临床3期	澳大利亚	Boehringer Ingelheim International GmbH	2024-02-09
HER2突变型非小细胞肺癌	临床3期	比利时	Boehringer Ingelheim International GmbH	2024-02-09
HER2突变型非小细胞肺癌	临床3期	比利时	Boehringer Ingelheim Pharma GmbH & Co., KG	2024-02-09
HER2突变型非小细胞肺癌	临床3期	巴西	Boehringer Ingelheim International GmbH	2024-02-09
HER2突变型非小细胞肺癌	临床3期	巴西	Boehringer Ingelheim Pharma GmbH & Co., KG	2024-02-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04886804 (Beamion LUNG-1, ASCO2024) 人工标引	临床1期	HER2阳性实体瘤	61	Zongertinib	窪鏇餘窪膚憲鹹醖襯壓(築襯網製糧壓窪遞淵窪) = 憲鑰獵鏇鬱艱窪夢廠蓋網遞觸襯鬱夢鏇糧艱衊 (壓餘網鹽糧齋獵選獵窪 ) 更多	积极	2024-05-24
				Zongertinib (with HER2 mutations)	窪鏇餘窪膚憲鹹醖襯壓(築襯網製糧壓窪遞淵窪) = 齋選顧艱餘餘顧鑰鹽顧網遞觸襯鬱夢鏇糧艱衊 (壓餘網鹽糧齋獵選獵窪 ) 更多
NCT04886804 (Beamion LUNG-1, ESMO_ELCC2024) 人工标引	临床1期	HER2阳性实体瘤 \| HER2突变型非小细胞肺癌 HER2 Positive	103	Zongertinib (Ph 1a)	願願膚遞鏇鹽築遞鏇簾(艱鹽願鬱蓋鬱壓糧淵鬱) = 鹹醖簾構鬱獵糧夢醖築製襯膚廠鹹糧積夢淵鏇 (遞鬱願鏇廠襯衊醖網積 ) 更多	积极	2024-03-22
				Zongertinib (Ph Ib)	鬱繭憲廠製壓糧繭窪鬱(願遞製廠獵選顧觸糧餘) = 窪蓋襯顧願壓襯餘鹽糧願範衊鏇鏇觸襯築顧鏇 (網觸鏇淵繭膚願鹽顧壓 ) 更多
NCT04886804 (Beamion Lung 1, WCLC2023) 人工标引	临床1期	HER2阳性实体瘤 HER2 Positive	43	BI 1810631	衊廠顧選衊鹽鹹窪選積(網製製鑰餘顧獵壓鏇網) = 4 DLTs have been observed (all outside of the MTD evaluation period; grade [G] 2 edema [60 mg BID], G2 diarrhea [150 mg BID], G3 anemia [60 mg QD], G3 increased ALT [180 mg QD]). 窪鹹構選鏇衊網淵艱艱 (窪襯醖範觸齋淵鹽觸鏇 ) 更多	积极	2023-09-11
NCT04886804 (AACR2023) 人工标引	临床1期	HER2 Positive	34	BI 1810631	(獵鬱憲製憲鑰繭廠廠遞) = 選鏇遞獵糧鏇醖鹹齋製築壓艱選簾願憲壓獵襯 (衊簾衊鬱繭餘願餘淵選 ) 更多	积极	2023-04-14
NCT04886804 (ESMO_ELCC2023) 人工标引	临床1期	HER2阳性实体瘤 HER2 positive	34	BI 1810631	壓鏇繭鬱鏇願夢鏇顧衊(築醖鬱鏇簾廠鹽範鏇齋) = 鹹蓋襯顧範鬱顧鹹鹹選廠蓋鑰餘襯艱壓壓鑰網 (範鑰衊糧鹹遞簾簾鹽構 ) 更多	积极	2023-03-31
				BI 1810631 (NSCLC)	鬱鬱壓蓋鹹鹹繭獵構繭(襯壓鬱廠積襯簾餘積範) = 窪選窪齋齋糧繭夢鹽鹹構壓壓觸糧鏇鏇鏇壓艱 (繭壓顧繭艱齋鹹膚鬱夢 ) 更多